Carsten Reinhardt Email

Managing Director and Chief Development Officer . Immatics Biotechnologies

Current Roles

Employees:
427
Revenue:
$120.2M
About
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. Our transformative product candidates are - best in class - Adoptive Cell Therapies and Bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics'? proprietary and world-leading XPRESIDENT® technology. Our mission is to bring the power of T-cell redirecting immunotherapies to cancer patients. QUICK FACTS - 150 Team members - >100 Targets covering 20 major solid and liquid tumors - About 80% of discovered targets are novel - 2 proprietary technology platforms - 8 proprietary development programs, thereof 2 in the clinic in 2017 - Multiple partnered programs - Raised more than $230m in cash in five financings Read more about Immatics on our homepage: https://immatics.com/ Find us on Twitter and XING: Twitter: http://bit.ly/2DFbPre XING: http://bit.ly/2E1Kkpv Legal notice: https://immatics.com/legal-notice.html
Immatics Biotechnologies Address
2201 W. Holcombe Blvd
Tuebingen, null
Germany
Immatics Biotechnologies Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.